STEMS Health Regenerative Medicine Miami
- PRP Therapy
- Arthritis Treatment
- Peptide Therapy
- Stem Cell Therapy
Miami Beach, FL
Miami Beach supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Mount Sinai Medical Center Miami Beach and nearby University of Miami, and stem cell practice in the area spans South Beach, Mid-Beach, and Sunset Harbour. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Florida has seen active FDA enforcement, most notably the 2019 permanent injunction against US Stem Cell Clinic in Sunrise after patients were blinded by adipose stem cell injections into their eyes. The Florida Board of Medicine licenses physicians, and the Department of Health Division of Medical Quality Assurance investigates clinics. There is no Florida-specific stem cell disclosure law, so federal rules under 21 CFR Part 1271 apply. The 4 Miami Beach clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Florida Board of Medicine licensure checks.
Regulatory context
Florida cellular therapy providers are governed by 21 CFR Part 1271. Section 361 applies to minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 applies to products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND or BLA. Most stem cell, stromal vascular fraction, exosome, umbilical cord blood derived, and culture-expanded mesenchymal cell therapies marketed in Florida for orthopedic, neurologic, autoimmune, and longevity indications fall under Section 351 and lack FDA approval. Florida is a high-volume market, which has translated into elevated federal scrutiny.
Florida has been a primary target of FDA enforcement. In US v US Stem Cell Inc (2019), a federal court in Florida granted a permanent injunction against a Sunrise-based clinic for marketing unapproved stem cell products derived from adipose tissue. The Eleventh Circuit upheld the injunction in 2021. The FDA has issued multiple warning letters to Florida clinics offering exosome and umbilical cord-derived therapies. The Florida Department of Health and the Boards of Medicine and Osteopathic Medicine have disciplined physicians for unprofessional conduct tied to misleading regenerative medicine marketing. The Florida Attorney General has pursued deceptive trade practice claims under FDUTPA against stem cell clinics.